KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Return on Invested Capital (2021 - 2023)

Historic Return on Invested Capital for AbCellera Biologics (ABCL) over the last 3 years, with Q4 2023 value amounting to 0.16%.

  • AbCellera Biologics' Return on Invested Capital fell 2800.0% to 0.16% in Q4 2023 from the same period last year, while for Dec 2023 it was 0.16%, marking a year-over-year decrease of 2800.0%. This contributed to the annual value of 0.23% for FY2024, which is 600.0% down from last year.
  • According to the latest figures from Q4 2023, AbCellera Biologics' Return on Invested Capital is 0.16%, which was down 2800.0% from 0.14% recorded in Q3 2023.
  • AbCellera Biologics' Return on Invested Capital's 5-year high stood at 0.19% during Q3 2022, with a 5-year trough of 0.16% in Q4 2023.
  • For the 3-year period, AbCellera Biologics' Return on Invested Capital averaged around 0.03%, with its median value being 0.11% (2022).
  • In the last 5 years, AbCellera Biologics' Return on Invested Capital plummeted by -300bps in 2022 and then tumbled by -3200bps in 2023.
  • Quarter analysis of 3 years shows AbCellera Biologics' Return on Invested Capital stood at 0.14% in 2021, then fell by -21bps to 0.11% in 2022, then plummeted by -246bps to 0.16% in 2023.
  • Its Return on Invested Capital stands at 0.16% for Q4 2023, versus 0.14% for Q3 2023 and 0.1% for Q2 2023.